HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5-(2-phenyl-3'-indolal)-2-thiohydantoin

structure in first source

Also Known As:

PIT cpd

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Imidazolidines: 39
        Hydantoins: 306
        Thiohydantoins: 19
        Phenylthiohydantoin: 1
        5-(2-phenyl-3'-indolal)-2-thiohydantoin: 1

Experts

1.	Buyukbingol, E: 1 article (04/2000)
2.	Suzen, S: 1 article (04/2000)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2000 - "5-(2-Phenyl-3'-indolal)-2-thiohydantoin (PIT) has been evaluated as an anti-cancer compound on several cancer lines organised in to subpanels representing leukemia, melanoma, and cancer of lung, colon, kidney, ovary, breast, prostate and central nervous system by the National Cancer Institute (NCI) anti-cancer drug screen programme. "
2.	Melanoma (Melanoma, Malignant) 04/01/2000 - "5-(2-Phenyl-3'-indolal)-2-thiohydantoin (PIT) has been evaluated as an anti-cancer compound on several cancer lines organised in to subpanels representing leukemia, melanoma, and cancer of lung, colon, kidney, ovary, breast, prostate and central nervous system by the National Cancer Institute (NCI) anti-cancer drug screen programme. "
3.	Lung Neoplasms (Lung Cancer) 04/01/2000 - "5-(2-Phenyl-3'-indolal)-2-thiohydantoin (PIT) has been evaluated as an anti-cancer compound on several cancer lines organised in to subpanels representing leukemia, melanoma, and cancer of lung, colon, kidney, ovary, breast, prostate and central nervous system by the National Cancer Institute (NCI) anti-cancer drug screen programme. "
4.	Leukemia 04/01/2000 - "5-(2-Phenyl-3'-indolal)-2-thiohydantoin (PIT) has been evaluated as an anti-cancer compound on several cancer lines organised in to subpanels representing leukemia, melanoma, and cancer of lung, colon, kidney, ovary, breast, prostate and central nervous system by the National Cancer Institute (NCI) anti-cancer drug screen programme. "